This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

E. Morrey Atkinson, III net worth and biography

E. Morrey Atkinson, III Biography and Net Worth

EVP of Vertex Pharmaceuticals

Throughout his decades-long career in the biopharmaceutical industry, Morrey has contributed his expertise in the development and commercialization of multiple modality therapeutics across all aspects of preclinical, clinical and commercial manufacturing including small molecules, biologics and cell therapies. He joined Vertex in 2020 and serves on the Executive Committee as Chief Technical Operations Officer and Head of Biopharmaceutical Sciences and Manufacturing Operations. In his role he oversees all aspects of our preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain functions.

He earned his bachelor’s degree in biology from Indiana University and his doctoral degree in biological sciences from Stanford University. Prior to Vertex, Morrey was the Senior Vice President of Global Manufacturing Operations at Bristol Myers Squibb (BMS) and was responsible for the global network of internal and external manufacturing for BMS commercial products. He joined BMS in 2012 as the Vice President of Biologics Development and progressed through various roles, including Vice President of Biologics Manufacturing and the Integration Leader for Manufacturing, Product Development and Cell Therapy during the Celgene-BMS Integration. Prior to BMS, Morrey’s career included various scientific and management roles of increasing responsibility at Eli Lilly and Company, Cook Pharmica (now Catalent) and Targeted Genetics Corporation.

Morrey serves on the board of directors for 89bio and is active in advocating for LGBTQ+ equality, including serving on the National Leadership Council for the Lambda Legal Defense and Education Fund. He is the executive sponsor for Vertex PRIDE, our employee resource network that supports, provides visibility of, and celebrates our LGBTQ+ employees and allies.

What is E. Morrey Atkinson, III's net worth?: The estimated net worth of E. Morrey Atkinson, III is at least $7.20 million as of June 12th, 2024. Dr. Atkinson, III owns 15,972 shares of Vertex Pharmaceuticals stock worth more than $7,202,893 as of November 24th. This net worth approximation does not reflect any other investments that Dr. Atkinson, III may own. Learn More about E. Morrey Atkinson, III's net worth.
How do I contact E. Morrey Atkinson, III?: The corporate mailing address for Dr. Atkinson, III and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on E. Morrey Atkinson, III's contact information.
Has E. Morrey Atkinson, III been buying or selling shares of Vertex Pharmaceuticals?: E. Morrey Atkinson, III has not been actively trading shares of Vertex Pharmaceuticals during the last ninety days. Most recently, Edward Morrow Atkinson III sold 7,288 shares of the business's stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $478.00, for a transaction totalling $3,483,664.00. Following the completion of the sale, the executive vice president now directly owns 15,972 shares of the company's stock, valued at $7,634,616. Learn More on E. Morrey Atkinson, III's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

E. Morrey Atkinson, III Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/12/2024	Sell	7,288	$478.00	$3,483,664.00	15,972

E. Morrey Atkinson, III Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $450.97

$449.04

$457.54

50 Day Range

MA: $474.11

$448.01

$516.74

2 Week Range

Now: $450.97

$346.29

$519.88

Volume

1,270,384 shs

Average Volume

1,345,841 shs

Market Capitalization

$116.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Nvidia’s world of pain awaits

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Click play to stream The Final Frontier at no cost